CN101268079B - 用于治疗疼痛的哒嗪酮衍生物 - Google Patents

用于治疗疼痛的哒嗪酮衍生物 Download PDF

Info

Publication number
CN101268079B
CN101268079B CN2006800322174A CN200680032217A CN101268079B CN 101268079 B CN101268079 B CN 101268079B CN 2006800322174 A CN2006800322174 A CN 2006800322174A CN 200680032217 A CN200680032217 A CN 200680032217A CN 101268079 B CN101268079 B CN 101268079B
Authority
CN
China
Prior art keywords
compound
methylphenyl
fluorophenyl
pyrimidin
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN2006800322174A
Other languages
English (en)
Chinese (zh)
Other versions
CN101268079A (zh
Inventor
山崎齐
笠原千义
洼田浩一
绀谷彻
浅野亨
水原日出一
横本正治
三隅启司
木下智彦
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wakunaga Pharmaceutical Co Ltd
Astellas Pharma Inc
Original Assignee
Wakunaga Pharmaceutical Co Ltd
Astellas Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wakunaga Pharmaceutical Co Ltd, Astellas Pharma Inc filed Critical Wakunaga Pharmaceutical Co Ltd
Publication of CN101268079A publication Critical patent/CN101268079A/zh
Application granted granted Critical
Publication of CN101268079B publication Critical patent/CN101268079B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/20—Spiro-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN2006800322174A 2005-09-01 2006-08-31 用于治疗疼痛的哒嗪酮衍生物 Expired - Fee Related CN101268079B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US71282505P 2005-09-01 2005-09-01
US60/712,825 2005-09-01
PCT/JP2006/317691 WO2007026950A1 (en) 2005-09-01 2006-08-31 Pyridazinone derivatives used for the treatment of pain

Publications (2)

Publication Number Publication Date
CN101268079A CN101268079A (zh) 2008-09-17
CN101268079B true CN101268079B (zh) 2011-09-14

Family

ID=37607561

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2006800322174A Expired - Fee Related CN101268079B (zh) 2005-09-01 2006-08-31 用于治疗疼痛的哒嗪酮衍生物

Country Status (13)

Country Link
US (1) US20090042856A1 (https=)
EP (1) EP1919919A1 (https=)
JP (1) JP5066516B2 (https=)
KR (1) KR20080049758A (https=)
CN (1) CN101268079B (https=)
AU (1) AU2006285599A1 (https=)
BR (1) BRPI0617100A2 (https=)
CA (1) CA2620740A1 (https=)
IL (1) IL189697A0 (https=)
NO (1) NO20081572L (https=)
RU (1) RU2008112290A (https=)
TW (1) TW200745034A (https=)
WO (1) WO2007026950A1 (https=)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200904421A (en) 2007-05-03 2009-02-01 Astellas Pharma Inc New compounds
WO2009005675A1 (en) 2007-06-28 2009-01-08 Abbott Laboratories Novel triazolopyridazines
CA2726588C (en) 2008-06-03 2019-04-16 Karl Kossen Compounds and methods for treating inflammatory and fibrotic disorders
EP2614053B1 (en) * 2010-09-08 2016-03-23 Sumitomo Chemical Company Limited Method for producing pyridazinone compounds and intermediates thereof
CN104039785A (zh) 2011-10-06 2014-09-10 拜耳知识产权有限责任公司 作为杀真菌剂的杂环基吡(嘧)啶基吡唑
JO3407B1 (ar) 2012-05-31 2019-10-20 Eisai R&D Man Co Ltd مركبات رباعي هيدرو بيرازولو بيريميدين
AR092742A1 (es) 2012-10-02 2015-04-29 Intermune Inc Piridinonas antifibroticas
HRP20170217T1 (hr) 2013-04-25 2017-04-21 Beigene, Ltd. Fuzinirani heterociklički spojevi kao inhibitori protein kinaze
EA034666B1 (ru) 2013-09-13 2020-03-04 Бейджин Свитзерланд Гмбх Антитело против pd-1 и его применение для лечения рака или вирусной инфекции и фрагмент антитела
MX382781B (es) 2014-04-02 2025-03-13 Intermune Inc Piridinonas anti-fibroticas.
TWI726608B (zh) 2014-07-03 2021-05-01 英屬開曼群島商百濟神州有限公司 抗pd-l1抗體及其作為治療及診斷之用途
CN106146404B (zh) * 2015-04-15 2020-03-20 江苏恩华药业股份有限公司 哒嗪酮类衍生物及其应用
US10864203B2 (en) 2016-07-05 2020-12-15 Beigene, Ltd. Combination of a PD-1 antagonist and a RAF inhibitor for treating cancer
CA3033827A1 (en) 2016-08-16 2018-02-22 Beigene, Ltd. Crystalline form of (s)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl )-4,5,6,7-tetra-hydropyrazolo[1,5-a]pyrimidine-3-carboxamide,preparation, and uses thereof
PT3500299T (pt) 2016-08-19 2024-02-21 Beigene Switzerland Gmbh Combinação de zanubrutinib com um anticorpo anti-cd20 ou anti-pd-1 para utilização no tratamento do cancro
CR20190157A (es) 2016-08-31 2019-08-13 Agios Pharmaceuticals Inc Inhibidores de procesos metabólicos celulares
WO2018119142A1 (en) 2016-12-21 2018-06-28 Amgen Inc. Anti-tnf alpha antibody formulations
EP3573989A4 (en) 2017-01-25 2020-11-18 Beigene, Ltd. CRYSTALLINE FORMS OF (S) -7- (1- (BUT-2-YNOYL) PIPERIDIN-4-YL) -2- (4-PHENOXYPHENYL) -4, 5, 6, 7-TETRAHY DROPYRAZOLO [1, 5-A ] PYRIMIDINE-3-CARBOXAMIDE, PREPARATION AND ASSOCIATED USES
EP3612522A4 (en) 2017-04-18 2021-07-07 Celgene Quanticel Research, Inc. THERAPEUTIC COMPOUNDS
TW202515616A (zh) 2017-06-26 2025-04-16 英屬開曼群島商百濟神州有限公司 抗pd-1抗體或其抗原結合片段在製備治療用於患有肝細胞癌(hcc)之藥物的用途
WO2019034009A1 (en) 2017-08-12 2019-02-21 Beigene, Ltd. BTK INHIBITOR WITH ENHANCED DOUBLE SELECTIVITY
US10342786B2 (en) 2017-10-05 2019-07-09 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
WO2019071147A1 (en) 2017-10-05 2019-04-11 Fulcrum Therapeutics, Inc. INHIBITORS OF KINASE P38 REDUCING EXPRESSION OF DUX4 GENE AND DOWNSTREAM GENES FOR THE TREATMENT OF FSHD
CN111801334B (zh) 2017-11-29 2023-06-09 百济神州瑞士有限责任公司 使用包含btk抑制剂的组合治疗惰性或侵袭性b-细胞淋巴瘤
WO2020249001A1 (zh) 2019-06-10 2020-12-17 百济神州瑞士有限责任公司 一种含有布鲁顿氏酪氨酸激酶抑制剂的口服固体片剂及其制备方法
TW202112368A (zh) 2019-06-13 2021-04-01 荷蘭商法西歐知識產權股份有限公司 用於治療有關dux4表現之疾病的抑制劑組合
US11786531B1 (en) 2022-06-08 2023-10-17 Beigene Switzerland Gmbh Methods of treating B-cell proliferative disorder

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5624931A (en) * 1991-09-09 1997-04-29 Fujisawa Pharmaceutical Co., Ltd. Pyrazole derivatives
WO2001040230A1 (en) * 1999-12-02 2001-06-07 Fujisawa Pharmaceutical Co., Ltd. Pyrazolopyrazines and their use as adenosine antagonists

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000069464A1 (en) * 1999-05-12 2000-11-23 Fujisawa Pharmaceutical Co., Ltd. Novel use
US20040152659A1 (en) * 1999-05-12 2004-08-05 Fujisawa Pharmaceutical Co. Ltd. Method for the treatment of parkinson's disease comprising administering an A1A2a receptor dual antagonist
WO2006038734A1 (en) * 2004-10-08 2006-04-13 Astellas Pharma Inc. Pyridazinone derivatives cytokines inhibitors

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5624931A (en) * 1991-09-09 1997-04-29 Fujisawa Pharmaceutical Co., Ltd. Pyrazole derivatives
WO2001040230A1 (en) * 1999-12-02 2001-06-07 Fujisawa Pharmaceutical Co., Ltd. Pyrazolopyrazines and their use as adenosine antagonists

Also Published As

Publication number Publication date
JP5066516B2 (ja) 2012-11-07
RU2008112290A (ru) 2009-10-10
EP1919919A1 (en) 2008-05-14
KR20080049758A (ko) 2008-06-04
BRPI0617100A2 (pt) 2011-07-12
IL189697A0 (en) 2008-06-05
JP2009507758A (ja) 2009-02-26
US20090042856A1 (en) 2009-02-12
CA2620740A1 (en) 2007-03-08
AU2006285599A1 (en) 2007-03-08
NO20081572L (no) 2008-03-31
CN101268079A (zh) 2008-09-17
TW200745034A (en) 2007-12-16
WO2007026950A1 (en) 2007-03-08

Similar Documents

Publication Publication Date Title
CN101268079B (zh) 用于治疗疼痛的哒嗪酮衍生物
CA2971024C (en) Fused ring heteroaryl compounds and their use as trk inhibitors
CN104470924B (zh) 作为tnf活性调节剂的咪唑并吡嗪衍生物
ES2654288T3 (es) Moduladores de P2X7
CN111819176A (zh) 4-氮杂吲哚化合物
KR20210044822A (ko) 피롤로피리미딘 itk 억제제
US20120095005A1 (en) Fused Bicyclic Pyrazole Derivatives As Kinase Inhibitors
KR20230173234A (ko) 인다졸계 화합물 및 관련된 사용 방법
CA2953798A1 (en) Aminopyridazinone compounds as protein kinase inhibitors
TW202309039A (zh) 用於靶向布魯頓氏酪胺酸激酶降解之化合物
EA030472B1 (ru) ПИРРОЛО[2,3-d]ПИРИМИДИНИЛ-, ПИРРОЛО[2,3-b]ПИРАЗИНИЛ- И ПИРРОЛО[2,3-d]ПИРИДИНИЛАКРИЛАМИДЫ
CN105732636A (zh) 杂芳化合物及其在药物中的应用
AU2012232658A1 (en) Substituted fused tricyclic compounds, compositions and medicinal applications thereof
CN104039784A (zh) 取代的增环嘧啶及其用途
KR20240026911A (ko) 골수성 세포 2 작용제 상에서 발현되는 유발 수용체로서의 헤테로고리 화합물 및 사용 방법
EP3145512A1 (en) Substituted ethynyl heterobicyclic compounds as tyrosine kinase inhibitors
CN114466850A (zh) [1,2,4]三唑并[1,5-c]喹唑啉-5-胺
CN115335057A (zh) 抑制酪蛋白激酶的方法
WO2016192630A1 (zh) 一类具有激酶抑制活性的化合物、制备方法和用途
CN104640865B (zh) 作为激酶抑制剂的二氢吡咯烷子基-嘧啶
CN112584898A (zh) P2x3受体拮抗剂
WO2016045598A1 (zh) 4-取代吡咯并[2,3-d]嘧啶化合物及其用途
CN101646673B (zh) 作为pkc抑制剂的3-氨基-吡咯并[3,4-c]吡唑-5(1h,4h,6h)甲醛衍生物
TW202317106A (zh) 作為egfr抑制劑之取代胺基吡啶化合物
WO2024175024A1 (zh) 作为CDKs抑制剂的新型并杂环类新化合物及其应用

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1124603

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20110914

Termination date: 20130831

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1124603

Country of ref document: HK